Is Novocure Ltd (NVCR) a Buy, Sell, or Hold?
NASDAQ : NVCR
Novocure Ltd
$17.65 USD
-$2.34 (-11.71%)
- Volume
- 3.88M
- Average Volume
- 1.88M
- Market Capitalization
- $2.04B
- P/E Ratio
- -13.58
- Dividend Yield
- 0.00%
- Price Target
- $26.00
- Year High
- $21.45
- Year Low
- $9.82
- Day High
- —
- Day Low
- —
- Payout Ratio
- $0.00
- Current Ratio
- $2.89
Company Overview
NASDAQ
Frank Leonard
Medical - Devices
Healthcare
NVCR
1605
CH
USD
Liquidity Metrics
0.69
2.89
2.70
0.42
0.00
Sales & Valuation
$655.35M
2.92
6.06
-96.77
-0.18
Profitability
-$1.22
-$136.23M
-21.25%
-21.84%
-44.00%
-18.68%
P/E Metrics
-13.58
-4.28
-4.28
Analyst Price Target & Rating
$26.00
$32.00
$20.00
1/5
15 Analysts
-32.12%
Financial Health Scores
1.15
5/9
$417.81M
$795.19M
$457.1M
-$148.96M
Key Metrics (TTM)
$2.18B
3.12
-16.25
2.89
-44.00%
-26.15%
-7.26%
-1.03%
-142 days
Company Executives
| Name | Title |
|---|---|
| Uri Weinberg | Chief Innovation Officer & Chief Medical Officer |
| Frank Leonard | Chief Executive Officer & Director |
| Michael Puri | Chief Human Resources Officer |
| William F. Doyle | Executive Chairman |
| Adam Daney | Head of Investor Relations |
| Christoph Brackmann | Chief Financial Officer |
| Barak Ben Arye | General Counsel |
| Mukund Paravasthu | Chief Operating Officer |
Poll Results
No votes yet today — be the first to share your view!
About Novocure Ltd (NASDAQ:NVCR) Stock
NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, France, Japan, Greater China, and internationally. Its TTFields devices include Optune Gio, Optune Lua, and Optune Pax. The company also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Baar, Switzerland. ...
NovoCure: Why I'm Fading The Q2 Earnings Rally
2026-07-24 13:45:46
NovoCure remains a Hold as recent gains and operational improvements do not alter its long-term, glioblastoma-centric outlook. Q2 revenue grew 16% Y/Y to $183.6M, with adjusted EBITDA guidance raised to $0–$15M, yet true cash generation remains elusive. Optune Pax's early uptake is promising but too preliminary to signal sustainable growth; its Q2 contribution was just $1.6M.
NovoCure's Clean Beat Signals A Shift Toward Profitability (Rating Upgrade)
2026-07-24 10:21:56
Novocure (NVCR) delivered a strong 2Q26 beat, raising full-year guidance to $710–$725 million and achieving positive adjusted EBITDA, signaling a credible path to profitability. NVCR's operating leverage is improving, with gross margins at 78% and net loss narrowing significantly, driven by 18% global active patient growth and expanding indications. Optune Pax's early launch shows promising adoption across academic and community settings, with repeat prescribing indicating potential for durable utilization and revenue upside.
NovoCure Limited (NVCR) Q2 2026 Earnings Call Transcript
2026-07-23 13:00:50
NovoCure Limited (NVCR) Q2 2026 Earnings Call Transcript
NovoCure (NVCR) Reports Q2 Loss, Beats Revenue Estimates
2026-07-23 09:16:05
NovoCure (NVCR) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.3. This compares to a loss of $0.36 per share a year ago.
NovoCure Q2 Earnings Call Highlights
2026-07-23 09:08:04
NovoCure NASDAQ: NVCR reported record second-quarter 2026 net revenue and active patient levels, with management pointing to growth across its approved products and improved expense discipline as it raised full-year revenue and adjusted EBITDA guidance.
Novocure Reports Second Quarter 2026 Financial Results
2026-07-23 08:00:00
Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to exte
Novocure Reports Second Quarter 2026 Financial Results
2026-07-23 07:00:00
BAAR, Switzerland--(BUSINESS WIRE)--Novocure (NASDAQ: NVCR) today reported financial results for the second quarter that ended June 30, 2026. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields). “This was our strongest quarter to date, with record net revenues and active patients on therapy,” said Frank Leonard, CEO, Novocure. “We continue to lau.
NovoCure (NVCR) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release
2026-07-16 11:06:22
NovoCure (NVCR) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Frequently Asked Questions
-
What is the current Novocure Ltd (NVCR) stock price?
-
Novocure Ltd(NASDAQ:NVCR) stock price is $17.65 in the last trading session. During the trading session, NVCR stock reached the peak price of $21.451 while $9.82 was the lowest point it dropped to. The percentage change in NVCR stock occurred in the recent session was --11.71% while the dollar amount for the price change in NVCR stock was -$2.34.
-
NVCR's industry and sector of operation?
-
The NASDAQ listed NVCR is part of Medical - Devices industry that operates in the broader Healthcare sector.
-
Who are the executives of NVCR?
-
Uri Weinberg | Chief Innovation Officer & Chief Medical Officer
Frank Leonard | Chief Executive Officer & Director
Michael Puri | Chief Human Resources Officer
William F. Doyle | Executive Chairman
Adam Daney | Head of Investor Relations -
How many employees does NVCR have?
-
Number of NVCR employees currently stands at 1605. NVCR operates from Neuhofstrasse 21, Baar, None 6340, CH.
-
Link for NVCR official website?
-
Official Website of NVCR is: https://www.novocure.com
-
How do I contact NVCR?
-
NVCR could be contacted at phone #44 15 3475 6700 and can also be accessed through its website. NVCR operates from Neuhofstrasse 21, Baar, None 6340, CH.
-
How many shares of NVCR are traded daily?
-
The average number of NVCR shares traded daily for last 3 months was 1.88M.
-
What is the market cap of NVCR currently?
-
The market value of NVCR currently stands at $2.04B with its latest stock price at $17.65